Seres Therapeutics Inc

NASDAQ:MCRB   11:15:48 AM EDT
7.56
+0.13 (+1.75%)
Products

Seres Announces Preliminary Ser-287 Phase 2B Eco-Reset Study Microbiome Data Analysis

Published: 12/16/2021 12:51 GMT
Seres Therapeutics Inc (MCRB) - Seres Announces Preliminary Ser-287 Phase 2b Eco-reset Study Microbiome Data Analysis.
Seres Therapeutics Inc - Microbiome Data Demonstrate Successful Engraftment of Ser-287.
Seres Therapeutics Inc - Microbiome Assessments Suggest Potential for Biomarker-based Patient Selection.
Seres Therapeutics Inc - Continues to Evaluate Ser-287 Study Data, and Available Preliminary Ser-301 Phase 1b Study Clinical and Microbiome Data.